Loading...
Research Project
Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic
Funder
Authors
Publications
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
Publication . Lanièce Delaunay, Charlotte; Martínez-Baz, Iván; Sève, Noémie; Domegan, Lisa; Mazagatos, Clara; Buda, Silke; Meijer, Adam; Kislaya, Irina; Pascu, Catalina; Carnahan, AnnaSara; Oroszi, Beatrix; Ilić, Maja; Maurel, Marine; Melo, Aryse; Sandonis Martín, Virginia; Trobajo-Sanmartín, Camino; Enouf, Vincent; McKenna, Adele; Pérez-Gimeno, Gloria; Goerlitz, Luise; de Lange, Marit; Rodrigues, Ana Paula; Lazar, Mihaela; Latorre-Margalef, Neus; Túri, Gergő; Castilla, Jesús; Falchi, Alessandra; Bennett, Charlene; Gallardo, Virtudes; Dürrwald, Ralf; Eggink, Dirk; Guiomar, Raquel; Popescu, Rodica; Riess, Maximilian; Horváth, Judit Krisztina; Casado, Itziar; García, M. del Carmen; Hooiveld, Mariëtte; Machado, Ausenda; Bacci, Sabrina; Kaczmarek, Marlena; Kissling, Esther
Background:
Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants.
Aim:
We aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases.
Methods:
This European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection.
Results:
Among adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%) < 90, 90–179 and ≥ 180 days post vaccination, respectively. Booster VE was 42% (95% CI: 32–51%) overall and 56% (95% CI: 47–64%), 22% (95% CI: 2–38%) and 3% (95% CI: −78% to 48%), respectively. Primary series VE was similar among adolescents. Restricting analyses to Comirnaty had little impact. Vaccine effectiveness was higher among older adults. There was no signal of bias due to correlation between COVID-19 and influenza vaccination. Confounding by previous infection was low, but sample size precluded definite assessment of effect modification.
Conclusion:
Primary series and booster VE against symptomatic infection with BA.1/BA.2 ranged from 37% to 42%, with similar waning post vaccination. Comprehensive data on previous SARS-CoV-2 infection would help disentangle vaccine- and infection-induced immunity.
I-MOVE-COVID-19: uma rede europeia para investigar, prevenir e controlar a pandemia da COVID-19
Publication . Gómez, Verónica; Machado, Ausenda; Rodrigues, Ana Paula; Kislaya, Irina; Conde, Patrícia; Costa, Inês; Cristóvão, Paula; Verdasca, Nuno; Guiomar, Raquel; Nunes, Baltazar
Face à pandemia da COVID-19, a vigilância epidemiológica tem um
papel fundamental para a deteção precoce de casos e a monitorização
da pandemia. A par com a vigilância epidemiológica, importa, também,
investigar fatores protetores e de risco para COVID-19, bem como
estimar a efetividade de intervenções para controlo da doença, desde a
efetividade de intervenções terapêuticas, como a vacina ou de medidas
de saúde pública. Para tal, a rede I-MOVE-COVID-19, composta por 23
parceiros europeus, de entre os quais Portugal, propõe-se a investigar
características epidemiológicas e clínicas de indivíduos com COVID-19,
bem como informações virológicas sobre SARS-CoV-2, através do
estabelecimento de uma plataforma de vigilância adaptável à situação
epidemiológica, de estudos de investigação e da avaliação de intervenções
de saúde pública.
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021
Publication . Kissling, Esther; Hooiveld, Mariette; Sandonis Martín, Virginia; Martínez-Baz, Iván; William, Naoma; Vilcu, Ana-Maria; Mazagatos, Clara; Domegan, Lisa; de Lusignan, Simon; Meijer, Adam; Machado, Ausenda; Brytting, Mia; Casado, Itziar; Murray, Josephine-L.K.; Belhillil, Sylvie; Larrauri, Amparo; O’Donnell, Joan; Tsang, Ruby; de Lange, Marit; Rodrigues, Ana Paula; Riess, Maximilian; Castilla, Jesús; Hamilton, Mark; Falchi, Alessandra; Pozo, Francisco; Dunford, Linda; Cogdale, Jade; Jansen, Tessa; Guiomar, Raquel; Enkirch, Theresa; Burgui, Cristina; Sigerson, Debbie; Blanchon, Thierry; Martínez Ochoa, Eva María; Connell, Jeff; Ellis, Joanna; van Gageldonk-Lafeber, Rianne; Kislaya, Irina; Rose, Angela M.C.; Gomez, Verónica; Nunes, Baltazar; Roquette, Rita; Silva, Adriana; Melo, Aryse; Costa, Inês; Verdasca, Nuno; Conde, Patrícia; Valenciano, Marta; I-MOVE-COVID-19 primary care study team
The I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight countries. We measured overall and product-specific COVID-19 VE against symptomatic SARS-CoV-2 infection among those aged 65 years and older. We also measured VE by time since vaccination.
Establishing a novel European hospital surveillance platform in response to a newly emerging infection lessons from the I-MOVE-COVID-19 hospital network
Publication . Ladbury, Georgia; Hamilton, Mark; Harvey, Ciaran; Mutch, Heather; McMahon, James; Mokogwu, Damilola; Sadiq, Fatima; Young, Johanna; Wallace, Lesley; Murray, Josie; Lopez‑Bernal, Jamie; Andrews, Nick; Castilla, Jesús; Casado, Itziar; Larrauri, Amparo; Mazagatos, Clara; Duval, Xavier; Bino, Silvia; Demuyser, Thomas; Machado, Ausenda; Mickiene, Aukse; Lazar, Mihaela; Stavaru, Crina; Rath, Barbara; Harrabi, Myriam; Rekacewicz, Claire; Kapisyszi, Perlat; Seyler, Lucie; Gómez, Verónica; Jancoriene, Ligita; Rose, Angela
Background:
The first signal of a new infection is often severe cases presenting at
hospital. Enhanced surveillance of these cases is critical to learning
more about disease epidemiology and patient outcomes, but nationallevel
surveillance can lack power to draw conclusions. In response
to the emergence of SARS-CoV-2, the Influenza-Monitoring Vaccine
Effectiveness (I-MOVE) network, founded in 2007, expanded to establish the I-MOVE-COVID-19 Consortium in February 2020. The Consortium’s
surveillance objectives included using pooled data to describe clinical
and epidemiological characteristics of hospitalised COVID-19 patients
across Europe, in order to contribute to the knowledge base, guide
patient management, and inform public health response.
Methods:
Eleven study sites participated in the surveillance, including 23 hospitals
across six EU Member States and Albania, and hospitals nationally in
England and Scotland. A standardised protocol and dataset for collection
was agreed by April 2020. In England and Scotland, data were generated
by linkage of routine datasets; other sites used bespoke paper or
electronic questionnaires. Data were submitted, pooled and analysed
quarterly.
Results:
Data were received regarding 84,297 COVID-19 patients hospitalised
between 1 February 2020 and 31 January 2021. Three surveillance
bulletins were published between September 2020 and March 2021,
providing key insights into severe COVID-19 at European level. However,
the unexpected, overwhelming workload at participating sites, and
difficulties securing data protection and ethics permissions, delayed
data submissions and presented challenges for timely analysis.
Conclusions:
Building on an existing network facilitated a novel European multicentre
hospital surveillance system to be implemented during a pandemic;
however, timeliness was nonetheless problematic. In future, processes
could be streamlined e.g. by developing pre-approved template protocols
with information governance and ethical approvals in place during the
inter- pandemic period.
Enhanced surveillance of COVID-19 in secondary care in Europe: a tale of two waves
Publication . Mokogwu, Damilola; Hamilton, Mark; Harvey, Ciaran; Elgohari, Suzanne; Burgui, Cristina; Mazagatos, Clara; Galtier, Florence; Seyler, Lucie; Machado, Ausenda; Jonikaite, Indre; Lazar, Mihaela; Rath, Barbara; Mutch, Heather; McMahon, James; Ladbury, Georgia; Akinnawo, Ayodele; Martínez-Baz, Iván; Larrauri, Amparo; Laine, Fabrice; Fico, Albana; Demuyser, Thomas; Kislaya, Irina; Gefenaite, Giedre; Cherciu, Carmen; Harrabi, Myriam; MC Rose, Angela; I-MOVE study group
Background:
The I-MOVE-COVID-19 Consortium was established to conduct
surveillance of hospitalised COVID-19 cases in nine European countries,
aiming to describe the clinical and epidemiological characteristics of
severe COVID-19 in order to inform public health response.
Methods:
Data are pooled from 11 participating sites; two (England and Scotland)
submitting national data, with the remainder being from a selection
of hospitals. Descriptive analysis is performed on the pooled dataset
overall and comparing data on patients admitted from week 5 to 28 of
2020 (“first wave”) vs those admitted later (“second wave”).
Results:
Data on 84,297 hospitalised patients were submitted for 01 February 2020
- 31 January 2021. Fifty-six percent of cases (46,907/84,193) were male
and median age was 69 years. Where information was available, 44%
(25,344 /57,769) patients were recorded as having at least one chronic
condition. Ninety-five percent (7,868/8,270 and 90% (5,606/6,231)
were reported with respiratory and febrile presentations respectively.
Twenty-four percent (18,795/78,955) were admitted to intensive care
units (ICU) and 26% (19,805/76,764) died in hospital (all sites); 12%
(3,305/28,262) and 20% (5,454/27,066) respectively for all sites except
England (where ICU reporting is mandated, biasing the dataset towards
more severe outcomes as this site represents >50% of all cases). As a
percentage of all hospital admissions, both ICU admissions and deaths
decreased significantly between the first and second waves in both sexes
and across all age- groups, apart from the over 75s.
Conclusions:
Results from this multicentre European surveillance system suggest that
about one in 10 hospitalised COVID-19 patients are admitted to ICU and
one in five have fatal outcomes. Fatality and ICU admission were lower in
the second wave compared with the first.
Organizational Units
Description
Keywords
Contributors
Funders
Funding agency
European Commission
Funding programme
H2020
Funding Award Number
101003673